1. Abbreviations used in this paper: ADCC, antibody-dependent cellular cytotoxicity; FCzR, receptor for the Fc domain of IgG; PIG, phosphatidylinositol glycan; PIPLC, phosphatidyl inositol-specific phospholipase C; PNH, paroxysmal nocturnal hemoglobinuria. protein, CD2, the E chain of CD3, and peptide receptors for PDGF, CSF-1, and IL-6 (13) .
There are two genes encoding the low avidity muFcRII proteins, muFclRIIa and muFcYRIIl3, which share 95% homology in the extracellular domains but differ in their transmembrane and cytoplasmic domains. The (20) (21) (22) IV.3 (35) huFczRIII FcfR10, FczRp5,7o NK cells, neutrophils, eosinophils, macrophages, not on monocytes 3G8, B73. 1, leu 1 la, b, c (34, 53, 59) The huFclRI is thought to play a role in antibody-dependent cellular cytotoxicity (ADCC) reactions. Graziano and Fanger (24) have demonstrated killing by monocytes of myelomas bearing both anti-huFczRI and anti-huFcRII MAb. IFN-,y, which in many systems acts to potentiate ADCC reactions and to enhance the oxidative burst (25) , increases the expression of . IFN-y treatment of U937 cells potentiates ADCC mediated by murine IgG2a (27), the subclass of mouse IgG that binds most avidly to huFczRI. In addition, IFN-y induces expression of huFczRI on neutrophils, which usually do not express this receptor (28) (29) (30) . The IFN-y-treated neutrophils have increased ADCC potential and mediate ADCC via the induced huFczRI (29) . Other agents, such as glucocorticoids and retinoic acid (30, 31) , and the CSa split product of complement (32) (38, 39 ). HuFczRII will direct ADCC by monocytes and the cytotoxic potential of this receptor is increased in neutrophils by treatment with IFN-y, although the density of huFcRII is not elevated by IFN-,y (24) . HuFc1RII may play a vital role in triggering the oxidative burst, since this response to aggregated IgG is blocked by MAb IV.3 or its F(ab')2 fragment (20 huFcRIII HuFc.zRIII, CD1 6, is expressed on neutrophils, NK cells, a minor population of T cells, eosinophils, and on tissue macrophages but not on monocytes (38, (53) (54) (55) . In the granulocyte lineage, huFczRIII is expressed at the metamyelocyte stage. The HL-60 promyelocytic cell line, which does not express huFczRIII, can be induced to do so by DMS0 or retinoic acid, which induces a more mature granulocytic morphology. The recent cloning and expression of huFczRIII in COS cells has facilitated a study of receptor specificity. HuFczRIII binds human IgGl and IgG3 with a Ka -5 X I05 M' and does not bind human IgG2 and IgG4 (56) . These results agree with previous results obtained by Spiegelberg et al. (57) and Gergely et al. (58) .
Several lines of evidence suggest that there may be a family of huFc.RIII molecules that have highly conserved extracellular domains but may differ in other domains. There are immunological differences between neutrophil and NK cell antigens that can be demonstrated with anti-FcYRIII MAbs, and the NA1/NA2 alloantigen system of huFc RIII is apparently restricted to neutrophils (59) . Analysis of SDS-PAGE of huFc7RIII immunoprecipitated from macrophages, neutrophils, and NK cells before and after deglycosylation also illustrates differences between these receptors. Isolation of huFc, RIII from monocytes cultured in vitro for 14 d revealed a protein of M, 55 ,000, which was not altered by digestion with N-glycanase (39). The neutrophil receptor, by contrast, exhibited a broad band on SDS-PAGE from 50,000-70,000 Mr, which is reduced to a doublet of 28,000-29,000 Mr after deglycosylation. The huFczRIII molecule on NK cells is also different from the neutrophil receptor, since deglycosylation leads to a complex pattern with peptides of 36,000, 40,000, and 44,000 Mr (60).
The neutrophil huFczRIII molecule has now been identified as a membrane protein that has a phosphatidylinositol glycan (PIG) membrane anchor (61, 62) . The neutrophil huFc,,RIII is released from the cells upon treatment with phosphatidyl inositol-specific phospholipase C (PIPLC). Furthermore, neutrophils from patients with PNH, an acquired clonal stem cell disorder characterized by a defect in the biosynthesis of the PIG anchor, show a marked deficiency in huFczRIII expression. Decay accelerating factor and acetylcholinesterase, two other PIG-anchored proteins, are also deficient in the membranes of patients with PNH. Both the NA1
and NA2 alloantigens of huFcyRIII are released by PIPLC.
Results of expression in COS cells on a cDNA encoding huFczRIII confirm the presence of a PIG anchor (56) . The functional significance of the PIG anchor on neutrophils remains to be determined. Huizinga et al. (62) HuFczRIII is present in high concentration on Kuppfer cells in the liver and on macrophages in the red pulp of the spleen, both loci involved in clearance of immune complexes. Blockade of the mononuclear phagocyte system of chimpanzees with either the anti-FcYRIII MAb 3G8 or its Fab fragment resulted in a dramatic blockade of in vivo clearance of autologous erythrocytes coated with antibody directed against a minor blood group antigen (67) . These results suggest that, at least for this type of large immune complex, huFczRIII on macrophages may be the major receptor involved in clearance. Blockade of huFclRIII by MAb 3G8 was tested as a therapeutic treatment of chronic immune thrombocytopenic purpura, a disease characterized by anti-platelet antibody (68) . Infusioh of 3G8 in one reported case had a dramatic short-term effect on platelet levels which rose to normal levels and subsided after 2 wk. Reinfusion of the MAb resulted in a blunted response, possibly due to production of antibodies against the murine IgG.
The huFcYRIII cloned by Simmons and Seed (56) using a eukaryotic expression shuttle vector from a cDNA library constructed from human placenta reveals greatest homology with the muFczRIIa gene. The predicted protein has a short transmembrane domain followed by only four residues, only one of which is basically charged. The recombinant huFctRIII expressed in COS cells is immunoreactive with a panel of anti-huFczRIII MAbs, has an Mr of 50,000-70,000, is reduced in size to 26,000 Mr after N-glycanase digestion, and is released from the membrane of transfected cells by digestion with PIPLC, all characteristics ofthe neutrophil huFcYRIII. There is a conflict, however, between the results of Simmons and Seed (56) , who state that the receptor they have isolated is that of NK (73) and neutrophils (74) has been reported to trigger Ca2" mobilization. This may, however, be a secondary phenomenon, since phagocytosis of EIgG is not inhibited after the free Ca2" is buffered to 1-10 nm by EGTA or Quin2 (75) . Phillips and Parker (76, 77) 
